Search for COVID-19 and Reopening Information Here

Can I use new drugs or therapeutics to treat COVID-19? Where do I get them?

Last Updated: 01/15/2022

COVID-19 Therapeutics Overview

The federal government has authorized several therapeutics to support the treatment and prevention of severe COVID-19 outcomes. None of these therapies are a substitute for COVID-19 vaccination and layered prevention measures are recommended.

There are significant nationwide supply shortages for all COVID-19 treatments. Quantities available to New Jersey and nationally remain very limited. Equitable access remains a priority.

We want to ensure access to treatment for as many people as possible, but, currently, the eligible population for each of these therapeutics is far larger than the supply available to our state.

The National Institutes of Health (NIH) have developed guidance on patient prioritization: Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints and overall Coronavirus Disease (COVID-19) Treatment Guidelines. The U.S. Department of Health and Human Services (HHS) has issued a Side-by-Side Overview of Outpatient Therapies Authorized for Treatment of Mild-Moderate COVID-19 to help patients and providers make informed decisions.

Oral Antiviral Treatments

Oral antivirals reduce the risk of hospitalization and death in patients at high-risk for severe COVID-19 when started early after COVID-19 symptom onset.

Authorized Outpatient Therapeutics

  1. Paxlovid (Pfizer)
  2. Molnupiravir (Merck)

Patient Profile

Eligibility Information

  1. Patient fact sheet for Paxlovid
  2. Patient fact sheet for Molnupiravir

Risks and Benefits

Health care providers should discuss the risks and benefits of treatment with their patients.

  1. Provider fact sheet for Paxlovid
  2. Provider fact sheet for Molnupiravir
  3. NIH Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19

Given scarcity, both products should be considered. However, Molnupiravir is only recommended whom alternative FDA-authorized options are not accessible or clinically appropriate.

Active Points of Dispensing

During the initial rollout, pharmacies will dispense the antivirals to patients with prescriptions. Walgreens locations across New Jersey are active.

The HHS COVID-19 Therapeutics Locator has a list of locations that have reported inventory on hand in the last day: https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/

Additional retail, specialty, and independent pharmacies will be added as supplies available to New Jersey increase. Some Federally Qualified Health Centers (FQHCs) will also start treating patients soon.

How to Access

Prescriptions are required. Healthcare providers should submit prescriptions to pharmacies through routine processes.

People who have started COVID-19 symptoms within the past five days should consult your healthcare provider about whether an oral antiviral is appropriate.

Federally Qualified Health Centers (FQHCs) are available to uninsured individuals.

Monoclonal Antibodies (mAbs) for Treatment

Monoclonal antibodies treat lab-confirmed mild-to-moderate COVID-19 by working against spike protein.

Authorized Outpatient Therapeutics

  1. Bamlanivimab/etesevimab (Lilly)
  2. Casirivimab/imdevimab REGEN-COV (Regeneron)
  3. Sotrovimab Xevudy (GSK)

Patient Profile

  • Have tested positive for COVID-19,
  • Have had symptoms for 10 days or fewer,
  • At high risk for progression to severe COVID-19, and
  • Meet therapy-specific inclusion/exclusion criteria (e.g. Lilly product is only available to neonates and those ages <12).

The Lilly and Regeneron products are also authorized for post-exposure prophylaxis (PEP). Given scarcity, providers should prioritize use as treatment.

Eligibility Information

  1. Patient fact sheet for Bamlanivimab/etesevimab
  2. Patient fact sheet for Casirivimab/imdevimab REGEN-COV
  3. Patient fact sheet for Sotrovimab

Risks and Benefits

Healthcare providers should discuss the risks and benefits of treatment with their patient:

  1. Provider fact sheet for Bamlanivimab/etesevimab
  2. Provider fact sheet for Casirivimab/imdevimab REGEN-COV
  3. Provider fact sheet for Sotrovimab
  4. NIH Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19

At this time, Sotrovimab the only authorized mAb expected to be effective for treatment against the Omicron variant, which is predominant in NJ.

Active Points of Dispensing

While a variety of site types have been used when mAbs were more readily available, during the current rollout, the focus for dispensing are: acute care hospitals, specialty pharmacies serving high-risk congregate settings, Federally Qualified Health Centers (FQHCs) and urgent care centers.

List of locations that received product this week.

How to Access

Please contact each site individually for product availability.

Monoclonal Antibodies (mAbs) for Pre-Exposure Prophylaxis

Over the past year, there have been an increasing variety of monoclonal antibodies authorized for treatment, for post-exposure prophlyaxis, and, now, for pre-exposure prophylaxis. The Evusheld product from AstraZeneca was authorized at the end of December for people 12 years and older who are not yet infected with COVID-19, but who are either moderately to severely immunocompromised or have a medical contraindication to all available COVID-19 vaccines.

Authorized Outpatient Therapeutics

  1. Evusheld / tixagevimab and cilgavimab (AstraZeneca)

Patient Profile

  • Not currently infected with SARS-CoV-2,
  • Have not had a known recent exposure SARS-CoV-2, and
  • Either:
    a. Have moderate to severe immune compromise and may not mount an adequate immune response to COVID-19 vaccination OR
    b. Has a medical contraindication to all available COVID-19 vaccines.

Eligibility Information

  1. Patient fact sheet for Evusheld

Risks and Benefits

Healthcare providers should discuss the risks and benefits of this therapy with their patient:

  1. Provider fact sheet for Evusheld

Active Points of Dispensing

During the initial rollout, acute care and specialty hospitals will dispense these mAbs to their existing high-risk patients. Specialty pharmacies serving high-risk congregate settings will be added as supplies increase.

The HHS COVID-19 Therapeutics Locator has a list of locations that have reported inventory on hand in the last day: https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/

How to Access

Please contact each site individually for product availability.